Related Experiment Video
Updated: Mar 9, 2026

Author Spotlight: Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System
Published on: May 12, 2023
Composite End Points in Clinical Trials of Heart Failure Therapy: How Do We Measure the Effect Size?
Paul M Brown1, Justin A Ezekowitz2
1From the Department of Medicine, University of Alberta, Edmonton, Canada (P.M.B.); and Canadian VIGOUR Centre, Edmonton, Canada (P.M.B., J.A.E.).
Abstract:
Composite end points are popular outcomes in clinical trials of heart failure therapies. For example, a global rank composite is typically analyzed using a Mann-Whitney U test, and the results are summarized by the mean of ranks and a corresponding P value. The mean of ranks is uninformative, and a clinically meaningful estimate of the treatment effect is needed to communicate study results and facilitate an assessment of heterogeneity (the consistency of the effect across outcomes). The probability index is intuitive for clinicians, easy to calculate, and may be applied to various composites. We suggest a simple and familiar plot to assess heterogeneity across outcomes, which should be routine when analyzing composites. We think that the probability index provides an immediate and simple solution to an overt problem.
More Related Videos
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Inotropic Agents
Heart Failure III: Clinical Manifestations